EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

SYLVANT

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IAIN/0041	A.1 - Administrative change - Change in the name and/or address of the MAH	17/07/2023		SmPC, Labelling and PL	
IB/0040	B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion	08/06/2023	n/a		

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

	of a non-significant in-process test				
IB/0039	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	08/02/2023		SmPC	
II/0038	Submission of the report from study ACCELERATE (Advancing Castleman Care with an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients with Castleman Disease - NCT02817997 listed as an obligation in the Annex II of the Product Information. This is a study Report to cover the data collected for 100 patients over a 5 year period in the ACCELERATE Registry study to collect information or patients with Castleman's Disease who are candidates to receive Sylvant or are currently receiving treatment with Sylvant. The obligation has now been fulfilled, the Annex II is updated accordingly. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	12/01/2023		Annex II	Not applicable
PSUSA/10254	Periodic Safety Update EU Single assessment -	01/12/2022	n/a		PRAC Recommendation - maintenance

/202204	siltuximab				
IAIN/0035	A.1 - Administrative change - Change in the name and/or address of the MAH	09/04/2021	29/04/2022	SmPC, Labelling and PL	
IB/0034	B.I.e.5.z - Implementation of changes foreseen in an approved change management protocol - Other variation	13/12/2019	n/a		
PSUSA/10254 /201904	Periodic Safety Update EU Single assessment - siltuximab	31/10/2019	n/a		PRAC Recommendation - maintenance
T/0033	Transfer of Marketing Authorisation	26/07/2019	03/09/2019	SmPC, Labelling and PL	
R/0029	Renewal of the marketing authorisation.	31/01/2019	02/04/2019	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of SYLVANT in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IB/0031	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	11/02/2019	n/a		
PSUSA/10254 /201804	Periodic Safety Update EU Single assessment - siltuximab	31/10/2018	n/a		PRAC Recommendation - maintenance
N/0030	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/10/2018	02/04/2019	PL	

PSUSA/10254 /201710	Periodic Safety Update EU Single assessment - siltuximab	17/05/2018	n/a		PRAC Recommendation - maintenance
II/0026/G	This was an application for a group of variations. Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the product information following final results from studies CNTO328MCD2001 and CNTO328MCD2002 listed as imposed obligation in the Annex II (ANX002 and ANX003). The Package Leaflet are updated accordingly. The RMP version 4.0 has also been submitted. In addition, the list of local representatives (Czech Republic, Lithuania and Portugal) in the PL is being revised C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	12/04/2018	02/04/2019	SmPC, Annex II and PL	An open-label, multicentre, non-randomised Phase 2 study assessed the safety and efficacy of extended treatment with siltuximab in 60 patients with MCD who were previously enrolled in Study 1 (41 patients) or Study 2 (19 patients). Median duration of siltuximab treatment was 5.52 years (range: 0.8 to 10.8 years); more than 50% of patients received siltuximab treatment for ≥5 years. After a median of 6 years of follow-up, none of the 60 patients had died and maintenance of disease control was demonstrated in 58 of 60 patients.
PSUSA/10254 /201704	Periodic Safety Update EU Single assessment - siltuximab	30/11/2017	n/a		PRAC Recommendation - maintenance
IB/0025	B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place	15/08/2017	n/a		

II/0023	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	06/07/2017	n/a		
IB/0022	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	17/05/2017	12/04/2018	SmPC and PL	
PSUSA/10254 /201610	Periodic Safety Update EU Single assessment - siltuximab	05/05/2017	n/a		PRAC Recommendation - maintenance
IB/0021	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	04/04/2017	n/a		
IA/0020/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	03/02/2017	11/04/2017	Annex II	
IB/0018	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	13/01/2017	11/04/2017	SmPC and PL	

IB/0017	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	01/12/2016	n/a		
PSUSA/10254 /201604	Periodic Safety Update EU Single assessment - siltuximab	01/12/2016	n/a		PRAC Recommendation - maintenance
IB/0015	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	27/10/2016	n/a		
IB/0016	B.I.a.z - Change in manufacture of the AS - Other variation	20/10/2016	n/a		
IB/0014/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)	04/08/2016	n/a		
PSUSA/10254 /201510	Periodic Safety Update EU Single assessment - siltuximab	13/05/2016	n/a		PRAC Recommendation - maintenance
IB/0012	C.I.z - Changes (Safety/Efficacy) of Human and	03/05/2016	11/04/2017	SmPC, Annex	

	Veterinary Medicinal Products - Other variation			II, Labelling and PL	
IB/0010	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	02/12/2015	n/a		
PSUSA/10254 /201504	Periodic Safety Update EU Single assessment - siltuximab	06/11/2015	n/a		PRAC Recommendation - maintenance
IB/0008	B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product	03/06/2015	17/07/2015	SmPC and PL	
PSUSA/10254 /201410	Periodic Safety Update EU Single assessment - siltuximab	07/05/2015	n/a		PRAC Recommendation - maintenance
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/03/2015	17/07/2015	Labelling	
IG/0531	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	05/03/2015	n/a		
IA/0005	A.6 - Administrative change - Change in ATC Code/ATC Vet Code	26/02/2015	17/07/2015	SmPC	
IB/0003/G	This was an application for a group of variations. B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits	30/12/2014	n/a		

	B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
IB/0002	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	07/10/2014	n/a		
IB/0001	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	10/07/2014	17/07/2015	SmPC and PL	